Combined Modality Therapy
Bristol Myers Advances Opdualag into Phase 3 Trials for First-Line Lung Cancer
Opdualag, Bristol Myers Squibb, lung cancer, first-line treatment, phase 3 trials, LAG-3/PD-1 combination therapy
GSK’s Zejula Fails to Meet Overall Survival Goal in First-Line Ovarian Cancer, Combination Therapy Disappoints
Zejula, niraparib, GSK, ovarian cancer, first-line treatment, overall survival, combination therapy, FDA, restriction, second-line maintenance
Merck’s Keytruda-Lenvima Combination Shows Promise in Liver Cancer Treatment
Keytruda, Lenvima, liver cancer, hepatocellular carcinoma, combination therapy, Merck, Eisai, clinical trials.
AstraZeneca Secures Landmark EU Approval for Imfinzi-Lynparza Combo in Endometrial Cancer Treatment
AstraZeneca, Imfinzi, Lynparza, endometrial cancer, EU approval, combination therapy, immunotherapy, PARP inhibitor, mismatch repair proficient, mismatch repair deficient
Vir Biotechnology Reports Positive Update on Hepatitis Delta Combination and Monotherapy Treatments
Vir Biotechnology, Hepatitis Delta, Combination Therapy, Monotherapy, Clinical Trial, EASL Congress
FDA Rejects Elevar and Hengrui Pharma’s Combination Therapy for Liver Cancer
FDA, Elevar Therapeutics, Hengrui Pharmaceuticals, liver cancer, combination therapy, rejection, clinical trials.
FDA Grants Approval to ImmunityBio’s Innovative Combination Therapy for Bladder Cancer
FDA, ImmunityBio, bladder cancer, combination therapy, approval, innovative treatment, immunotherapy, clinical trials
FDA Greenlights Idorsia’s Aprocitentan (Tryvio) for Resistant Hypertension Patients
FDA approval, Idorsia, Aprocitentan, Tryvio, Resistant hypertension, Endothelin receptor antagonist, Systolic blood pressure, Uncontrolled hypertension, Combination therapy, Clinical trials, PRECISION study, Recommended dosage: 12.5 mg, Availability: Second half of 2024, Edema and fluid retention side effects
Brukinsa by BeiGene Secures FDA Approval for Follicular Lymphoma Amid Imbruvica Setbacks
Brukinsa (zanubrutinib), BeiGene, FDA approval, follicular lymphoma, accelerated approval, obinutuzumab (Gazyva) combination therapy, ROSEWOOD trial, overall response rate (ORR), disease progression or unacceptable toxicity, competition with CAR-T cell therapies/ bispecific antibodies
Brukinsa Broadens Horizons: FDA Clears Follicular Lymphoma Combination Therapy
Brukinsa, Follicular lymphoma, FDA approval, BTK inhibitor, BTK inhibitor, Broadest label, Relapsed or refractory follicular lymphoma, ROSEWOOD Phase II study, CHMP positive opinion, Obinutuzumab combination therapy, Accelerated approval, Relapsed or refractory follicular lymphoma, Relapsed or refractory marginal zone lymphoma, Chronic lymphoma, CHMP recommendation, Phase II ROSEWOOD trial, Overall response rate (OR